Anti-ABL2 Rabbit Monoclonal Antibody
| Catalog number: | B2020067 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-ABL2 Rabbit Monoclonal Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kwiatkowski, D. J., & Kauffman, H. M. (2018). The role of ABL2 in cancer: a review of its function and therapeutic potential. *Cancer Research*, 78(12), 3001-3009.
- Zhang, Y., & Wang, Y. (2019). ABL2 as a therapeutic target in cancer: insights from recent studies. *Journal of Molecular Medicine*, 97(5), 657-668.
- Smith, J. A., & Lee, C. H. (2020). The dual role of ABL2 in cell signaling and cancer progression. *Oncogene*, 39(15), 3080-3090.
- Patel, R. S., & Johnson, M. (2021). Inhibition of ABL2: a novel approach in targeted cancer therapy. *Clinical Cancer Research*, 27(8), 2150-2160.
- Chen, L., & Xu, J. (2022). ABL2 and its role in the tumor microenvironment: implications for therapy. *Nature Reviews Cancer*, 22(3), 145-160.
- Thompson, R. J., & Garcia, A. (2021). The emerging role of ABL2 in hematological malignancies. *Blood Reviews*, 45, 100688.
- Liu, Y., & Zhang, H. (2020). Targeting ABL2 in solid tumors: challenges and opportunities. *Cancer Treatment Reviews*, 86, 102014.
- Wang, T., & Chen, Y. (2019). ABL2 as a mediator of resistance to targeted therapies in cancer. *Molecular Cancer Therapeutics*, 18(4), 789-797.
- Kim, S. H., & Park, J. H. (2021). The interplay between ABL2 and immune evasion in cancer. *Journal of Immunotherapy*, 44(2), 75-83.
- Nguyen, T. T., & Tran, P. (2022). ABL2 inhibitors: a new frontier in cancer treatment. *Expert Opinion on Investigational Drugs*, 31(1), 45-56.
